Xeris Biopharma declares positive results from phase 2 study of investigational XeriSol-formulated once-weekly SC levothyroxine to treat hypothyroidism

Xeris Biopharma Holdings, Inc., a biopharmaceutical company dedicated to advancing patient care, has unveiled promising results from its phase 2 trial of XP-8121 for treating hypothyroidism in adults. XP-8121, utilizing XeriSol formulation technology, offers a novel once-weekly subcutaneous (SC) injection of levothyroxine, significantly enhancing its bioavailability. The phase 2 study, involving 46 patients, aimed to determine the target dose conversion factor from daily oral levothyroxine to XP-8121 and assess its safety. Participants transitioned from stable oral doses to XP-8121 injections, reaching a weekly dose of 324.4 ± 125.59 mcg. Adverse events were mostly mild or moderate, with fatigue being the most common. Injection site reactions were minimal, and patient satisfaction was notably higher with XP-8121 compared to oral levothyroxine. The XeriSol formulation technology, designed for peptide and small molecule drugs, offers stable, ready-to-use formulations, potentially revolutionizing hypothyroidism treatment.